stoxline Quote Chart Rank Option Currency Glossary
  
EyeGate Pharmaceuticals, Inc. (EYEG)
35.42  0.04 (0.11%)    02-05 16:00
Open: 35.4156
High: 35.42
Volume: 24
  
Pre. Close: 35.38
Low: 35.4156
Market Cap: 25(M)
Technical analysis
2025-02-06 10:47:48 AM
Short term     
Mid term     
Targets 6-month :  41.37 1-year :  48.32
Resists First :  35.41 Second :  41.37
Pivot price 35.14
Supports First :  34.88 Second :  34.55
MAs MA(5) :  35.22 MA(20) :  35.02
MA(100) :  35.9 MA(250) :  35.7
MACD MACD :  -0.1 Signal :  -0.1
%K %D K(14,3) :  83 D(3) :  82.2
RSI RSI(14): 58
52-week High :  37.24 Low :  34.52
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.
[ EYEG ] has closed below upper band by 0.1%. Bollinger Bands are 36.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 35.19 - 35.39 35.39 - 35.57
Low: 34.48 - 34.74 34.74 - 34.98
Close: 34.74 - 35.12 35.12 - 35.47
Company Description

EyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. The company is headquartered in Waltham, Massachusetts and currently employs 11 full-time employees. The firm is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The firm's lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System. The firm is developing EGP-437 for the treatment of various inflammatory conditions of the eye, including uveitis, a debilitating form of intraocular inflammation of the anterior portion of the uvea, such as the iris and/or ciliary body, and macular edema, an abnormal thickening of the macula associated with the accumulation of excess fluids in the extracellular space of the neurosensory retina. The EyeGate II Delivery System is designed to deliver optimal quantities of drugs to the anterior or posterior segments of the eye.

Headline News

Mon, 30 Sep 2024
Perfluorohexyloctane ophthalmic solution for dry eye disease: pooled analysis of two phase 3 clinical trials - Frontiers

Mon, 17 Apr 2023
Global Ocular Drug Delivery System Market Size, Report - 2030 - Spherical Insights

Mon, 08 Nov 2021
EyeGate is Now Kiora Pharmaceuticals; Provides Update on Company’s Sharpened Clinical Development Strategy - GlobeNewswire

Mon, 14 Jun 2021
EyeGate Pharma announces first patient dosed in phase 2 ocular surface inflammation study - Ophthalmology Times

Tue, 14 Jan 2020
Managing Dry Eye Disease and Facilitating Realistic - ResearchGate

Fri, 22 Nov 2019
Eyegate sees top-line corneal wound win as unlocking path to U.S. de novo filing - BioWorld Online

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Underperform
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Underperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Neutral
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Underperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Underperform
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Outperform
Stock Basics & Statistics
Exchange:
NASDAQ
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 0 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 0 (%)
Shares Short 0 (K)
Shares Short P.Month 0 (K)
Stock Financials
EPS 0
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 0
Profit Margin 0 %
Operating Margin 0 %
Return on Assets (ttm) 0 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 0 %
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 0 (M)
Levered Free Cash Flow 0 (M)
Stock Valuations
PE Ratio 0
PEG Ratio 0
Price to Book value 0
Price to Sales 0
Price to Cash Flow 0
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android